• Mashup Score: 9
    KEYLYNK-007: olaparib and pembrolizumab in HRRm cancers - 6 day(s) ago

    Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the Phase II KEYLYNK-007 trial (NCT04123366) of olaparib and pembrolizumab in patients with advanced solid tumors harboring homologous recombination repair mutations (HRRm) or deficiencies. The combination demonstrated encouraging antitumor activity, especially in BRCA-mutated tumors, with responses observed across a wide range of cancer types. Treatment was generally well tolerated. Ongoing biomarker analyses aim to further clarify predictors of response in this tumor-agnostic approach. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjoncology.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      🎥Timothy Yap, MBBS, PhD, of @MDAndersonNews shares results from KEYLYNK-007: olaparib + pembro shows promising activity in HRR-mutant advanced tumors, especially BRCA-mutated. Tolerable and tumor-agnostic: ➡️https://t.co/6M39xYNJAf⬅️ @AACR #AACR25 #ImmunoOnc #TrialUpdate #CTSM

  • Mashup Score: 3
    Elucidating the role of abemaciclib in bladder cancer - 8 day(s) ago

    Bishoy Faltas, MD, Weill Cornell Medicine, New York, NY, comments on the value of on-target activity in RNA-seq analysis and its implications for treatment response in the CLONEVO trial (NCT03837821). Decreases in E2F pathway scores, which are associated with CDK4 and CDK6-induced phosphorylation of Rb, are a predictor of response to abemaciclib in bladder cancer. Sequential abemaciclib treatment can enhance the efficacy of antibody-drug conjugates, such as enfortumab vedotin, in combination with immune checkpoint inhibition, leading to improved outcomes in clinical trials. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjoncology.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      🎥@FaltasLab from @WeillCornell highlights CLONEVO trial data: E2F score drop via RNA-seq predicts abemaciclib response in bladder cancer. Sequential use boosts ADC + immunotherapy efficacy ➡️https://t.co/DVaQ6aD19o⬅️ @AACR #AACR25 #UroOnc #UroSoMe #Blcsm #ImmunoOnc

Load More